{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancers&page=2",
    "query": {
      "condition": "Ovarian Cancers",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancers&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T09:34:04.950Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04354246",
      "title": "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Ovarian Cancer",
        "Lung Cancer",
        "Colon Cancer",
        "Plasma Cell Neoplasm",
        "Multiple Myeloma",
        "HNSCC",
        "Microsatellite Stable Colorectal Carcinoma",
        "MSS-CRC"
      ],
      "interventions": [
        {
          "name": "Dose escalation: COM902 monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort expansion: COM902 (RDFE) monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: COM902 in combination with COM701 (both at the RDFE).",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Compugen Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2020-03-31",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 9,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04354246"
    },
    {
      "nct_id": "NCT03943173",
      "title": "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "BRCA-Mutated Ovarian Carcinoma",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "High Grade Fallopian Tube Serous Adenocarcinoma",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA Fallopian Tube Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Fallopian Tube Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Primary Peritoneal Cancer AJCC v8",
        "Stage IIIC Fallopian Tube Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Primary Peritoneal Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2019-06-07",
      "completion_date": "2027-06-27",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03943173"
    },
    {
      "nct_id": "NCT03073525",
      "title": "A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Gynecological Cancers",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2017-05-31",
      "completion_date": "2022-05-18",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 6,
      "location_summary": "Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03073525"
    },
    {
      "nct_id": "NCT02657889",
      "title": "Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Triple Negative Breast Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Stage IV Breast Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "niraparib",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2016-04-15",
      "completion_date": "2021-09-17",
      "has_results": true,
      "last_update_posted_date": "2022-12-01",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02657889"
    },
    {
      "nct_id": "NCT02107066",
      "title": "Women's Activity and Lifestyle Study in Connecticut",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 144,
      "start_date": "2009-05",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2018-04-20",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02107066"
    },
    {
      "nct_id": "NCT00529022",
      "title": "Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 36,
      "start_date": "2007-08",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00529022"
    },
    {
      "nct_id": "NCT06188520",
      "title": "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ER+ HER2- Advanced Breast Cancer",
        "High-grade Serous Ovarian Cancer (HGSOC)"
      ],
      "interventions": [
        {
          "name": "AZD8421",
          "type": "DRUG"
        },
        {
          "name": "Camizestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 564,
      "start_date": "2023-12-05",
      "completion_date": "2027-08-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06188520"
    },
    {
      "nct_id": "NCT07303894",
      "title": "A Study of Isoquercetin in People With Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Epithelial Ovarian Cancer",
        "Serous Ovarian Tumor"
      ],
      "interventions": [
        {
          "name": "Isoquercetin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-01-22",
      "completion_date": "2032-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 8,
      "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07303894"
    },
    {
      "nct_id": "NCT02878980",
      "title": "An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 0,
      "start_date": "2016-09-02",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02878980"
    },
    {
      "nct_id": "NCT01495663",
      "title": "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "I-131-CLR1404",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cellectar Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-12",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-02-26",
      "last_synced_at": "2026-06-25T09:34:04.950Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495663"
    }
  ]
}